Cargando…

Pemafibrate, a potent selective peroxisome proliferator-activated receptor α modulator, a promising novel treatment for ischemic retinopathy?

Detalles Bibliográficos
Autores principales:	Lee, Deokho, Tomita, Yohei, Negishi, Kazuno, Kurihara, Toshihide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075098/ https://www.ncbi.nlm.nih.gov/pubmed/36571350 http://dx.doi.org/10.4103/1673-5374.360319

Ejemplares similares

Pemafibrate prevents choroidal neovascularization in a mouse model of neovascular age-related macular degeneration
por: Lee, Deokho, et al.
Publicado: (2023)

Pemafibrate Prevents Retinal Dysfunction in a Mouse Model of Unilateral Common Carotid Artery Occlusion
por: Lee, Deokho, et al.
Publicado: (2021)

Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)

Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy
por: Tomita, Yohei, et al.
Publicado: (2021)

Ocular Ischemic Syndrome and Its Related Experimental Models
por: Lee, Deokho, et al.
Publicado: (2022)

Degeneration of retinal ganglion cells in hypoxic responses: hypoxia-inducible factor inhibition, a new therapeutic insight
por: Lee, Deokho, et al.
Publicado: (2022)

PPARα Modulation-Based Therapy in Central Nervous System Diseases
por: Lee, Deokho, et al.
Publicado: (2021)

PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)

Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model
por: Tomita, Yohei, et al.
Publicado: (2019)

Retinal Diseases Regulated by Hypoxia—Basic and Clinical Perspectives: A Comprehensive Review
por: Shinojima, Ari, et al.
Publicado: (2021)

Retinal Degeneration in a Murine Model of Retinal Ischemia by Unilateral Common Carotid Artery Occlusion
por: Lee, Deokho, et al.
Publicado: (2021)

Nicotinamide Mononucleotide Prevents Retinal Dysfunction in a Mouse Model of Retinal Ischemia/Reperfusion Injury
por: Lee, Deokho, et al.
Publicado: (2022)

Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate
por: Sasaki, Yusuke, et al.
Publicado: (2019)

Opsin 5 mediates violet light-induced early growth response-1 expression in the mouse retina
por: Jeong, Heonuk, et al.
Publicado: (2023)

Topical Application of Bunazosin Hydrochloride Suppresses Myopia Progression With an Increase in Choroidal Blood Perfusion
por: Jeong, Heonuk, et al.
Publicado: (2023)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemia
por: Fujioka, Yoshio
Publicado: (2018)

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
por: Iitake, Chie, et al.
Publicado: (2020)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
por: Fruchart, Jean-Charles, et al.
Publicado: (2021)

Molecular and Cellular Regulations in the Development of the Choroidal Circulation System
por: Imanishi, Satoshi, et al.
Publicado: (2023)

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice
por: Araki, Masaya, et al.
Publicado: (2018)

Non-Perfusion Area Index for Prognostic Prediction in Diabetic Retinopathy
por: Ofuji, Yoshiko, et al.
Publicado: (2022)

Nicotinamide Mononucleotide Protects against Retinal Dysfunction in a Murine Model of Carotid Artery Occlusion
por: Lee, Deokho, et al.
Publicado: (2022)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
por: Yokote, Koutaro, et al.
Publicado: (2019)

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia
por: Fruchart, Jean-Charles
Publicado: (2017)

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
por: Matsuba, Ikuro, et al.
Publicado: (2018)

Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice
por: Suto, Kumiko, et al.
Publicado: (2021)

Highly Selective PPARα (Peroxisome Proliferator‐Activated Receptor α) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular‐Microstructural Imaging
por: Iwata, Hiroshi, et al.
Publicado: (2021)

Associations between fatty acid intake and diabetic retinopathy in a Japanese population
por: Sasaki, Mariko, et al.
Publicado: (2023)

Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice
por: Zhang, Zhe, et al.
Publicado: (2022)

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
por: Nakajima, Atsushi, et al.
Publicado: (2021)

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
por: Honda, Yasushi, et al.
Publicado: (2017)

Highly sensitive visual restoration and protection via ectopic expression of chimeric rhodopsin in mice
por: Katada, Yusaku, et al.
Publicado: (2023)

Starburst amacrine cells amplify optogenetic visual restoration through gap junctions
por: Katada, Yusaku, et al.
Publicado: (2023)

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Fenofibrate Protects against Retinal Dysfunction in a Murine Model of Common Carotid Artery Occlusion-Induced Ocular Ischemia
por: Lee, Deokho, et al.
Publicado: (2021)

Multiple Factors Causing Myopia and the Possible Treatments: A Mini Review
por: Shinojima, Ari, et al.
Publicado: (2022)

Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events
por: Izumida, Toshihide, et al.
Publicado: (2022)

Violet Light Transmission is Related to Myopia Progression in Adult High Myopia
por: Torii, Hidemasa, et al.
Publicado: (2017)

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0lht5p2jpl8hke8a67mdo6j13b